Arsenic trioxide sensitizes promonocytic leukemia cells to TNFα-induced apoptosis via p38-MAPK-regulated activation of both receptor-mediated and mitochondrial pathways

Biochimica et Biophysica Acta - Molecular Cell Research

Volumn 1773, Issue 11, 2007, Pages 1653-1663

  Amrán, Donna ^a,b   Sánchez, Yolanda ^a   Fernández, Carlos ^a   Ramos, Adrián M ^a   de Blas, Elena ^a   Bréard, Jacqueline ^c   Calle, Consuelo ^b   Aller, Patricio ^a  

^a CENTRO DE INVESTIGACIONES BIOLÓGICAS   (Spain)

^b UNIVERSIDAD COMPLUTENSE DE MADRID   (Spain)

^c INSERM   (France)

Author keywords

Apoptosis; Arsenic trioxide; Mitochondrial pathway; Myeloid leukemia cell; Receptor mediated pathway; TNF

Indexed keywords

1,4 DIAMINO 1,4 BIS(2 AMINOPHENYLTHIO) 2,3 DICYANOBUTADIENE; 2 (2 AMINO 3 METHOXYPHENYL)CHROMONE; 2 MORPHOLINO 8 PHENYLCHROMONE; 4 (4 FLUOROPHENYL) 2 (4 METHYLSULFINYLPHENYL) 5 (4 PYRIDYL)IMIDAZOLE; 5 (2 AMINO 4 PYRIMIDINYL) 4 (4 FLUOROPHENYL) 1 (4 PIPERIDINYL)IMIDAZOLE; ANTHRA[1,9 CD]PYRAZOL 6(2H) ONE; ARSENIC TRIOXIDE; BENZYLOXYCARBONYLISOLEUCYLGLUTAMYLTHREONYLASPARTYL FLUOROMETHYL KETONE; BENZYLOXYCARBONYLVALYLALANYLASPARTYL FLUOROMETHYL KETONE; CASPASE 3; CASPASE 9; CYTOCHROME C; FLICE INHIBITORY PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE P38; PROTEIN BAX; PROTEIN BCL 2; TRANSCRIPTION FACTOR RELA; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RECEPTOR 1; X LINKED INHIBITOR OF APOPTOSIS;

APOPTOSIS; ARTICLE; CONTROLLED STUDY; ENZYME ACTIVATION; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; LEUKEMIA CELL; MITOCHONDRION; MYELOID LEUKEMIA; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN TARGETING; SIGNAL TRANSDUCTION;

ANTINEOPLASTIC AGENTS; APOPTOSIS; ARSENICALS; CELL LINE, TUMOR; CYTOKINES; ENZYME ACTIVATION; ENZYME INHIBITORS; GLUTATHIONE; HUMANS; LEUKEMIA; MAP KINASE SIGNALING SYSTEM; MITOCHONDRIA; MYELOID CELLS; NF-KAPPA B; OXIDES; P38 MITOGEN-ACTIVATED PROTEIN KINASES; PHOSPHORYLATION; PROTO-ONCOGENE PROTEINS C-AKT; PROTO-ONCOGENE PROTEINS C-BCL-2; RECEPTORS, CELL SURFACE; TUMOR NECROSIS FACTOR-ALPHA;

EID: 35548998655     PISSN: 01674889     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bbamcr.2007.06.003     Document Type: Article

References (43)

1. Miller Jr. W.M., Schipper H.M., Lee J.S., Singer J., and Waxman S. Mechanisms of action of arsenic trioxide. Cancer Res. 62 (2002) 3893-3903
2. Shi H., Shi X., and Liu K.J. Oxidative mechanisms of arsenic toxicity and carcinogenesis. Mol. Cell. Biochem. 255 (2004) 67-78
3. Evens A.M., Tallman M.S., and Gartenhaus R.B. The potential role of arsenic trioxide in the treatment of malignant disease: past, present and future. Leuk. Res. 28 (2004) 891-900
4. Larochette N., Decaudin D., Jacotot E., Brenner C., Marzo I., Susin S.A., Zamzami N., Xie Z., Reed J., and Kroemer G. Arsenite induces apoptosis via direct effect on the mitochondrial permeability transition pore. Exp. Cell Res. 249 (1999) 413-421
5. Pelicano H., Feng L., Zhou Y., Carew J.S., Hileman E.O., Plunkett W., Keating M.J., and Heng P. Inhibition of mitochondrial respiration. A novel strategy to enhance drug-induced apoptosis in human leukaemia cells by reactive oxygen species-mediated mechanism. J. Biol. Chem. 278 (2003) 37832-37839
6. Fulda S., and Debatin K.M. Extrinsic versus intrinsic apoptosis pathways in anticancer chemotherapy. Oncogene 25 (2006) 4798-4811
7. Kimberley F.C., and Screaton G.R. Following a TRAIL: update on a ligand and its five receptors. Cell Res. 14 (2004) 359-372
8. Kettelhut I.C., Fiers W., and Godberg A.L. The toxic effect of tumour necrosis factor in vivo and their prevention by cyclooxygenase inhibitors. Proc. Natl. Acad. Sci. U. S. A. 84 (1987) 4273-4277
9. Schotte P., Van Loo G., Carpentier I., Vandenabeele P., and Beyaert R. Lithium sensitizes tumor cells in a NF-κB-independent way to caspase activation and apoptosis induced by tumor Necrosis Factor (TNF). Evidence for a role of the TNF receptor-associated death domain protein. J. Biol. Chem. 276 (2001) 25939-25945
10. Duverger V., Murphy A.M., Sheehan D., England K., Cotter T.G., Hayes I., and Muphy F.J. The anticancer drug mithramycin A sensitizes tumour cells to apoptosis induced by tumour necrosis factor (TNF). Br. J. Cancer 90 (2004) 2025-2031
11. 2/M cell cycle arrest, activation of caspase-8 or caspase-9, and synergy with APO2/TRAIL. Blood 101 (2003) 4078-4087
12. Szegezdi E., Cahill S., Meyer M., O'Dwyer M., and Samali A. TRAIL sensitization by arsenic trioxide is caspase-8 dependent and involves modulation of death receptor components and Akt. Br. J. Cancer 94 (2006) 398-406
13. Jing Y., Dai J., Chalmers-Redman R.M., Tatton W.G., and Waxman S. Arsenic trioxide selectively induces acute promyelocytic leukaemia cell apoptosis via a hydrogen peroxide-dependent pathway. Blood 94 (1999) 2102-2111
14. Cossariza A., Franceschi C., Monti D., Salvioli S., Bellesia E., Rivabene R., Biondo L., Rinaldi G., Tinari A., and Malorni W. Protective effect of N-acetylcysteine in tumor necrosis factor-alpha-induced apoptosis in U937 cells: the role of mitochondria. Exp. Cell Res. 220 (1995) 232-240
15. Renvoize, Roger R., Moulian N., Bertoglio J., and Bréard J. Bcl-2 expression in target cells leads to functional inhibition of caspase-3 protease family in human NK and lymphokine-activated killer cell granule-mediated apoptosis. J. Immunol. 159 (1997) 126-134
16. Ramos A.M., Fernández C., Amrán D., Esteban D., de Blas E., Palacios M.A., and Aller P. Pharmacologic inhibitors of extracellular signal-regulated kinase (ERKs) and c-Jun NH2-terminal kinase (JNK) decrease glutathione content and sensitize human promonocytic leukemia cells to arsenic trioxide-induced apoptosis. J. Cell. Physiol. 209 (2006) 1006-1015
17. Troyano A., Sancho P., Fernández C., de Blas E., Bernardi P., and Aller P. The selection between apoptosis and necrosis is differentially regulated in hydrogen peroxide-treated and glutathione-depleted human promonocytic cells. Cell Death Differ. 10 (2003) 889-898
18. Troyano A., Fernández C., Sancho P., de Blas E., and Aller P. Effect of glutathione depletion on antitumor drug toxicity (apoptosis and necrosis) in U-937 human promonocytic cells. J. Biol. Chem. 276 (2001) 14115-47107
19. Schreiber E.P., Matthias P., Müller M.M., and Schaffner W. Identification of a novel lymphoid-specific octamer binding protein (OTF-2B) by proteolytic clipping bandshift assay (PCBA). EMBO J. 7 (1988) 4221-4229
20. López-Rodríguez C., Zubiaur M., Sancho J., Concha A., and Corbí A.L. An octamer element functions as a regulatory element in the differentiation-responsive CD11c integrin gene promoter: OCT-2 inducibility during myelomononcytic differentiation. J. Immunol. 158 (1997) 5833-5840
21. Schmelz K., Wieder T., Tamm I., Müller A., Essmann F., Geilen C.C., Schulze-Osthoff K., Dörken B., and Daniel P.T. Tumor necrosis factor α sensitizes malignant cells to chemotherapeutic drugs via the mitochondrial apoptosis pathway independently of caspase-8 and NF-κB. Oncogene 23 (2004) 6743-6759
22. Muñoz-Pinedo C., Ruiz-Ruiz C., Ruiz de Almodóvar C., Palacios C., and López-Rivas A. Inhibition of glucose metabolism sensitizes tumor cells to death receptor-triggered apoptosis through enhancement of death-inducing signalling complex formation and apical procaspase-8 processing. J. Biol. Chem. 278 (2003) 12759-12768
23. Choi Y.J., Park J.W., Suh S.I., Mun K.C., Bar J.H., Song D.K., Kim S.P., and Kwon T.K. Arsenic trioxide-induced apoptosis in U937 cells involve generation of reactive oxygen species and inhibition of Akt. Int. J. Oncol. 21 (2002) 603-610
24. Pelicano H., Carew J.S., McQueen T.J., Andreeff M., Plukett W., Keating M.J., and Huang P. Targeting Hsp90 by 17-AGG in leukemia cells: mechanisms for synergistic and antagonistic drug combinations with arsenic trioxide and Ara-C. Leukemia 20 (2006) 610-619
25. Tabellini G., Cappellini A., Tazzari P.L., Falà F., Billi A.M., Manzoli L., Cocco L., and Martelli A.M. Phosphinositide 3-kinase/Akt involvement in arsenic trioxide resistance of human leukemia cells. J. Cell. Physiol. 202 (2005) 623-634
26. Ramos A.M., Fernández A., Amrán D., Sancho P., de Blas E., and Aller P. Pharmacologic inhibitors of PI3K/Akt potentiate the apoptotic action of the antileukemic drug arsenic trioxide via glutathione depletion and increased peroxide accumulation in myeloid leukemia cells. Blood 105 (2005) 4013-4025
27. Wajant H., Pfizenmaier K., and Scheurich P. Tumor necrosis factor signalling. Cell Death Differ. 10 (2003) 45-65
28. Mathas S., Lietz A., Janz M., Hinz H.M., Jundt F., Scheidereit C., Bommert K., and Dorken B. Inhibition of NF-κB essentially contributes to arsenic-induced apoptosis. Blood 102 (2003) 1028-1034
29. Fernández C., Ramos A.M., Sancho P., Amrán D., de Blas E., and Aller P. 12-O-tetradecanoylphorbol-13-acetate may both potentiate and decrease the generation of apoptosis by the antileukemic agent arsenic trioxide in human promonocytic cells. Regulation by extracellular signal-regulated protein kinases and glutathione. J. Biol. Chem. 279 (2004) 3877-3884
30. Bergeron S., Beauchmin M., and Bertrand R. Camptothecin- and etoposide-induced apoptosis in human leukemia cells is independent of cell death receptor-3 and -4 aggregation but accelerates tumour necrosis factor-related apoptosis-inducing ligand-mediated cell death. Mol. Cancer Ther. 3 (2004) 1659-1669
31. Akay C., and Gazitt Y. Arsenic trioxide selectively induces early and extensive apoptosis via the APO2/caspase-8 pathway engaging the mitochondrial pathway in myeloma cells with mutant p53. Cell Cycle 2 (2003) 358-368
32. Kircelly F., Akay C., and Gazitt Y. Arsenic trioxide induces p53-dependent apoptotic signals in myeloma cells with SiRNA-silenced p53: MAP kinase pathway is preferentially activated in cells expressing inactivated p53. Int. J. Oncol. 30 (2007) 993-1001
33. Kanno S., Higurashi A., Watanabe Y., Shouji A., Asou K., and Ishikawa M. Susceptibility to cytosine arabinoside (Ara-C)-induced cytotoxicity in human leukaemia cells. Toxicol. Lett. 152 (2004) 149-158
34. Kim B.J., Ryu S.W., and Song B.J. JNK- and p38 kinase-mediated phosphorylation of Bax leads to its activation, and mitochondrial translocation and apoptosis of human hepatoma HepG2 cells. J. Biol. Chem. 281 (2006) 21256-21265
35. Rosato R.R., Dai Y., Almenara J.A., Maggio S.C., and Grant S. Potent anti-leukemic interactions between flavopiridol and TRAIL/Apo2L involve flavopiridol-mediated XIAP downregulation. Leukaemia 18 (2004) 1780-1788
36. Kater A.P., Dicker F., Mangiola M., Welsh K., Houghtne R., Ostresh J., Nefzi A., Reed J.C., Pinilla C., and Kipps T.J. Inhibitors of XIAP sensitize CD40-activated chronic lymphocytic leukaemia cells to CD-95 mediated apoptosis. Blood 106 (2005) 1742-1748
37. Bortul R., Tazzari P.L., Cappellini A., Tabellini G., Billi A.M., Bareggi R., Manzoli L., Cocco L., and Martelli A.M. Constitutively active Akt1 protects HL60 leukaemia cells from TRAIL-induced apoptosis through a mechanisms involving NF-kappaB activation and cFLIP(L) up-regulation. Leukaemia 17 (2003) 379-389
38. Kim S.K., Woodcroft K.J., Khodadadeh S.S., and Novak R.F. Insulin signaling regulates gamma-glutamyl-cysteine ligase catalytic subunit expression in primary cultured rat hepatocytes. J. Pharmacol. Exp. Ther. 311 (2004) 99-108
39. Zhang H.G., Wang J., Yang X., Hsu H.C., and Mountz J.D. Regulation of apoptosis proteins in cancer cells by ubiquitin. Oncogene 23 (2004) 2009-2015
40. Yang Y., Fang S., Jensen J.P., Weissman A.M., and Ashwell J.D. Ubiquitin protein ligase activity of IAPs and their degradation in proteasomes in response to apoptotic stimuli. Science 288 (2000) 874-877
41. Bredfeldt T., Kopplin M.J., and Gandolfi A.J. Effects of arsenite on UROtsa cells: low-level arsenite causes accumulation of ubiquitinated proteins that is enhanced by reduction in cellular glutathione levels. Toxicol. Appl. Pharmacol. 198 (2004) 412-418
42. Van Loo G., Van Gurp M., Depuydt B., Srinivasula S.M., Rodríguez I., Alnemri E.S., Gevaert K., Vandekerckhove J., Declercq W., and Vandenabeele P. The serine protease Omi/HtrA2 is released from mitochondria during apoptosis. Omi interacts with caspase-inhibitor XIAP and induces enhanced caspase activity. Cell Death Differ. 9 (2002) 20-26
43. Srinivasula S.M., Gupta S., Datta P., Zhang Z., Hedge R., Cheong N., Fernandes-Alnemri T., and Alnemri E.S. Inhibitor of apoptosis proteins are substrates for the mitochondrial serine protease Omi/HtrA2. J. Biol. Chem. 278 (2003) 31469-31472